TY  - GEN
AU  - Lanasa,Mark C
AU  - Davis,Patricia H
AU  - Datto,Michael
AU  - Li,Zhiguo
AU  - Gockerman,Jon P
AU  - Moore,Joseph O
AU  - DeCastro,Carlos M
AU  - Friedman,Daphne R
AU  - Diehl,Louis F
AU  - Rehder,Catherine
AU  - Cook,Harry
AU  - Daugherty,F Joseph
AU  - Matta,Karen M B
AU  - Weinberg,J Brice
AU  - Rizzieri,David
TI  - Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia
SN  - 1029-2403
PY  - 2012///0525
KW  - Aged
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Cyclophosphamide
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Leukemia, Lymphocytic, Chronic, B-Cell
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - genetics
KW  - Oligonucleotides
KW  - Prognosis
KW  - Risk Factors
KW  - Rituximab
KW  - Survival Rate
KW  - Tumor Suppressor Protein p53
KW  - antagonists & inhibitors
KW  - Vidarabine
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S
UR  - https://doi.org/10.3109/10428194.2011.610012
ER  -